Detalhe da pesquisa
1.
Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report.
JTO Clin Res Rep
; 5(4): 100647, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38550296
2.
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
J Thorac Oncol
; 19(6): 928-940, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38278303
3.
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression.
Curr Oncol
; 30(8): 7499-7507, 2023 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37623024
4.
Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.
JAMA Netw Open
; 6(7): e2325332, 2023 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37490292
5.
There Is an Unmet Need for Another Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Inhibitor.
J Thorac Oncol
; 17(10): 1175-1177, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36192078